The AIR Shortlist · Week 46 · 9 Nov – 13 Nov 2026

Under the radar stocks: five filings that changed AIR's read

The material filings that moved AIR's read the most, ranked by the size of the change in fundamentals, news flow, recognition and the discovery gap. Price-driven readings — momentum and value — are shown as facts and never count toward the rank.

  1. 01 · Major contract

    IBP · Installed Building Products, Inc. · All industries

    8-K · Items 1.01, 3.02 — Material agreement

    IBP completed acquisition of Old Dominion Group for $698M enterprise value, adding $370M LTM revenue and $68M EBITDA. Expands commercial end-market exposure from ~20% to ~28%, expected immediately accretive to revenue, margins, and EPS with $6-8M run-rate synergies.

    AIR's read

    News flow: Balanced 49 → Balanced 54Recognition: Watch 38 → Watch 43Gap Low · 0 → Very high · 72

    The filings read more positively.

    More of the market is starting to notice.

    Progress is running ahead of attention.

    The price trend strengthened.

    8-K · Filed 12 Nov 2026 · Filing · IBP on AIR

  2. 02 · Major contract

    COUR · Coursera, Inc. · Software / SaaS

    8-K · Items 1.01, 3.03 — Material agreement

    Coursera adopted a limited-duration stockholder rights plan in response to a shareholder accumulating 14.7% ownership. The plan triggers at 15% ownership, allowing other shareholders to purchase stock at 50% discount or forces exchange. Rights expire November 7, 2027.

    AIR's read

    News flow: Balanced 54 → Balanced 49Gap Very high · 65 → Low · 0

    The filings read less positively.

    The gap closed as the filings read less positively.

    • Also filed: 8-K · Item 2.05 — Exit or disposal costs (10 Nov 2026)

    8-K · Filed 9 Nov 2026 · Filing · COUR on AIR

  3. 03 · Major contract

    SRRK · Scholar Rock Holding Corp · Biotech

    8-K · Items 1.01, 2.02 — Material agreement

    Scholar Rock achieved FDA approval and U.S. launch of ISEMBYLD (apitegromab) for SMA in September 2026, generating $0.6M Q3 revenue. Company agreed to sell PRV for $205M cash. European and Japanese regulatory submissions advancing. Strong early demand reported.

    AIR's read

    News flow: Balanced 50 → Balanced 53Gap Low · 9 → Very high · 57

    The filings read more positively.

    Progress is running ahead of attention.

    The price trend weakened.

    • Also filed: Quarterly report (10-Q), period ending 30 Sep 2026 (10 Nov 2026)

    8-K · Filed 10 Nov 2026 · Filing · SRRK on AIR

  4. 04 · Major contract

    ASTE · Astec Industries Inc · All industries

    8-K · Item 1.01 — Material agreement

    Astec agreed to sell Roadtec and Carlson businesses to Komatsu for $75M enterprise value. Sale eliminates operating losses, expected to improve adjusted EBITDA margin ~200 bps and be accretive to EPS. Closes Q1 2027.

    AIR's read

    Gap Low · 3 → Very high · 45

    Progress is running ahead of attention.

    8-K · Filed 12 Nov 2026 · Filing · ASTE on AIR

  5. 05 · Results

    CRMD · CorMedix Inc. · Biotech

    8-K · Item 2.02 — Results of operations

    Q3 2026 revenue of $54.5M beat consensus ($51.2M). Announced definitive agreement to acquire Heron Therapeutics assets (expected $125–150M annual revenue contribution in 2027, immediately accretive). FDA granted Priority Review for REZZAYO sNDA (PDUFA Q1 2027). Secured $150M term loan facility.

    AIR's read

    News flow: Balanced 52 → Balanced 56Recognition: Balanced 46 → Watch 43Gap Very high · 48 → Very high · 87

    The filings read more positively.

    Market attention has faded.

    Progress is running ahead of attention.

    The price trend weakened.

    • Also filed: Quarterly report (10-Q), period ending 30 Sep 2026 (12 Nov 2026)
    • Also filed: Current report (8-K) (10 Nov 2026)
    • Also filed: 8-K · Items 1.01, 2.03, 3.02 — Material agreement (9 Nov 2026)

    8-K · Filed 12 Nov 2026 · Filing · CRMD on AIR

Every filing on the Radar →

Weeks

Research, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.